[1] Bian L, Wang Y, Yao X, et al.Coxsackievirus A6:a new emerging pathogen causing hand, foot and mouth disease outbreaks worldwide[J]. ExPert Rev Anti Infect Ther, 2015,13(9):1061-1071. [2] Crabol Y, Pean P, Mey C, et al.A Prospective, comparative study of severe neurological and uncomplicated hand, foot and mouth forms of paediatric enterovirus 71 infections[J]. Int J Infect Dis,2017,59:69-76. [3] Xie J, Jiao Y, Qiu Z, et al.Significant elevation of B cells at the acute stage in enterovirus 71-infected children with central nervous system involvement[J]. Scand J Infect Dis, 2010,42(11-12):931-935. [4] Lin YW, Chang KC, Kao CM,et al.Lymphocyte and antibody responses reduce enterovirus 71 lethality in mice by decreasing tissue viral loads[J]. J Virol,2009,83(13):6477-6483. [5] Wang SM, Lei HY, Huang KJ, et al.Pathogenesis of enterovirus 71 brainstem encephalitis in pediatric patients:roles of cytokines and cellular immune activation in patients with pulmonary edema[J]. J Infect Dis,2003,188(4):564-570. [6] Wong SS, YiP CC, Lau SK, et al.Human enterovirus 71 and hand, foot and mouth disease[J]. Epidemiol Infect,2010,138(8):1071-1089. [7] 钟晓, 张晓丽, 郑振喜.CVA6型手足口病影响因素分析[J]. 热带医学杂志,2015,15(5):696-698. [8] 程丽华, 王艳, 杨光.手足口病患者肠道病毒感染特征分析[J]. 中国病原生物学杂志, 2018,31(2):199-201. [9] Zhu FC, Liang ZL, Meng FY, et al.Retrospective study of the incidence of HFMD and seroepidemiology of antibodies against EV71 and CoxA16 in prenatal women and their infants[J]. PLoS One,2012,7:e37206. [10] Second J, Velter C, Cales S, et al.Clinicopathologic analysis of atypical hand, foot, and mouth disease in adult patients[J]. J Am Acad Dermatol,2017,76(4):722-729. [11] 李景良.重组柯萨奇A16病毒致病机理及候选疫苗对动物模型致死性保护机制[D].长春:吉林大学,2014. [12] Zhou Y, Shen C, Zhang C, et al.Yeast-produced recombinant virus-like particles of coxsackievirus A6 elicited protective antibodies in mice[J]. Antiviral Res, 2016,132:165-169. [13] Shen C, Ku Z, Zhou Y, et al.Virus-like particle-based vaccine against coxsackievirus A6 protects mice against lethal infections[J]. Vaccine,2016,34(34):4025-4031. [14] Chang LY, Huang LM, Gau SS, et al.Neurodevelopment and cognition in children after enterovirus 71 infection[J]. N Engl J Med,2007,356(12):1226-1234. [15] Chang LY, Hsiung CA, Lu CY, et al.Status of cellular rather than humoral immunity is correlated with clinical outcome of enterovirus 71[J]. Pediatr Res,2006,60(4):466-471. [16] Plas DR, Rathmell JC, Thompson CB.Homeostatic control of lymphocyte survival:potential origins and implications[J]. Nat Immunol,2002,3(6):515-521. [17] Chang LY, Hsia SH, Wu CT, et al.Outcome of enterovirus 71 infections with or without stage-based management:1998 to 2002[J]. Pediatr Infect Dis J,2004,23(4):327-332. [18] Hsia SH, Wu CT, Chang JJ, et al.Predictors of unfavorable outcomes in enterovirus 71-related cardiopulmonary failure in children[J]. Pediatr Infect Dis J,2005,24:331-334. [19] 郑亚明, 姜黎黎, 嵇红.手足口病重症病例分析:基于全国手足口病监测试点数据[J]. 中华流行病学杂志,2017,38(6):759-762. [20] 王燕霞.浅谈手足口病的防治[J]. 中国全科医学,2017,20(Suppl 2):158-160. |